Table 3

Bone marrow morphological and immunophenotypic characteristics
Number	Cellularity	Type of infiltrate	Percentage of LGLs	Phenotype by IHC	Phenotype by flow cytometry	RCP	GP	Meg	LN

1	N	IC, IVL	35	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	2⁺, 3⁺, 4^-, 5⁺, 7^+/-↓, 8⁺, 16^+/-, 56^-, 57⁺	N	D, LSM	N	+
2	N	IC, IVL	30	3⁺, 4^-, 8⁺, 57⁺, gr B^+/-	ND	N	I, LSM	N	+
3	N	IC	50	3⁺, 4^-, 8⁺, 57^+/-, gr B⁺	2⁺, 3⁺, 4^-, 5^+/-↓, 7⁺, 8⁺, 16^+/-, 56^-, 57⁺, TCRαβ⁺, TCRγδ^-	N	D, LSM	N	-
4	I	IC, IVL	58	ND	2⁺, 3⁺, 4^-, 5^-, 7^+/-↓, 8⁺,16^+/-, 56^-, 57^-, 43⁺↓, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR^+/-	D	N, LSM	N	+
5^a	D	IC, IVL	15	3⁺, 4^-, 8^-, 57⁺, gr B^+/-	2⁺, 3⁺, 4^-, 5^+/-↓, 7⁺, 8^-, 16^+/-, 56^+/-, 57^-, 43⁺, 25^-, TCRαβ^-, TCRγδ⁺, HLA-DR⁺and 2⁺, 3⁺, 4^-, 5^-, 7⁺, 8^+/-, 16⁺, 56^+/-, 57⁺, 43⁺, 25^-, TCRαβ^-, TCRγδ⁺, HLA-DR⁺	N	N, LSM	N	+
6	I	IC	40	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	ND	N	D, LSM	N	+
7	I	IC	80	3⁺, 4^-, 8^-/+, 57^+/-, gr B⁺	2⁺, 3⁺, 4^-, 5⁺, 7^+/-↓, 8^+/-, 16^+/-, 56^+/-, 57⁺, TCRαβ^-, TCRγδ⁺, HLA-DR^+/-	N	D, LSM	N	-
8	N	IC, IVL	25	3⁺, 4⁺, 8^-, 57⁺, gr B⁺	ND	N	D, LSM	N	+
9	I	IC, IVL	35	3⁺, 4⁺, 8⁺, 57⁺, gr B^+/-	ND	N	D, LSM	D	+
10	I	DI	15	3⁺, 4^-, 8⁺, 57^+/-, gr B^+/-	2⁺, 3⁺, 4^-, 5⁺, 7⁺, 8⁺, 16^+/-, 56^+/-, 57^+/-, HLA-DR^-/+	N	I, LSM	N	+
11	D	DI	15	3⁺, 4^-, 8⁺, 57^+/-gr B^+/-	2⁺, 3⁺, 4^-, 5⁺, 7⁺, 8⁺, 16^+/-, 56^-, 57^+/-	N	D, LSM	N	-
12	I	IC, IVL	50	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	2⁺, 3⁺, 4^-, 5^+/-↓, 7⁺, 8⁺, 16⁺, 56^+/-, 57^+/-, 25^-, HLA-DR^+/-	N	D, LSM	N	+
13	D	IC, IVL	20	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	2⁺, 3⁺, 4^-, 5⁺, 7^-↓, 8⁺, 16⁺, 56^-, 57^+/-, 43⁺↓, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR⁺	D	N, LSM	N	-
14	I	IC	20	3⁺, 4^-, 8⁺, 57^-, gr B^+/-	2⁺, 3⁺, 4^-, 5⁺, 7^+/-↓, 8⁺, 16^+/-, 56^-, 57^-, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR^+/-	D	N, LSM	N	-
15	I	IC, IVL	20	3⁺, 4^-, 8⁺, 57^-, gr B⁺	2⁺, 3⁺, 4^-, 5^-↓, 7^-↓, 8⁺, 16^+/-, 56^-, 57^-, 43⁺↓, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR^+/-	N	D, LSM	N	+
16	N	IC, IVL	25	3⁺, 4^-, 8⁺, 57⁺, gr B^+/-	2⁺, 3⁺, 4^-, 5^-↓, 7^-↓, 8⁺, 16^+/-, 56^-, TCRαβ⁺, TCRγδ^-, HLA-DR⁺	N	D, LSM	N	+
17	D	IC, IVL	60	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	2⁺, 3⁺, 4^-, 5^-↓, 7^-↓, 8⁺	N	D, LSM	N	-
18	I	IC, IVL	25	3⁺, 4^-, 8⁺, 57^+/-, gr B⁺	2⁺, 3^+/-↓, 4^-, 5^+/-↓, 7^+/-↓, 8⁺, 16⁺, 56^-, 57^+/-, 43⁺↓, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR⁺	N	N, LSM	N	-
19	I	IC	30	3⁺, 4^-, 8⁺, 57^+/-, gr B⁺	2⁺, 3⁺, 4^-, 5⁺, 7^+/-↓, 8⁺, 16⁺, 56^-, 57^+/-, 25^-, TCRαβ⁺, TCRγδ^-, HLA-DR⁺	D	N, LSM	D	+
20	D	IC, IVL	25	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	ND	D	N, LSM	N	+
21	I	IC, IVL	25	3⁺, 4^-, 8⁺, 57⁺, gr B⁺	ND	N	D, LSM	N	+

^aTwo cell populations. Expression of antigens: -, lack of antigen expression; +/-, partial expression varying from 20% to 95% of cells; +, expression of antigens on 100% of cells; ↓, abnormal expression (dim, partial, or negative expression) and CD43 (weaker level). D, decreased; DI, dispersed; GP, granulocyte precursors; gr B, granzyme B; I, increased; IC, interstitial clusters; IHC, immunohistochemistry (phenotype in expression of CD markers); IVL, intravascular lymphocytes; LGLs, large granular lymphocytes; LN, lymphoid nodules; LSM, left-shifted maturation; Meg, megakaryocyte; N, normal; ND, not done; RCP, red cell precursors; TCR, T-cell receptor.
Prochorec-Sobieszek et al. Arthritis Research & Therapy 2008 10:R55 doi:10.1186/ar2424